IRC
NVO

Investors Research Corp’s Novo Nordisk NVO Stock Holding History

Investors Research Corp’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$676K Sell
17,825
-400
-2% -$18.4K 0.12% 136
2026
Q2 		$874K Sell
18,225
-250
-1% -$10.7K 0.16% 111
2026
Q1 		$679K Buy
+18,475
New +$875K 0.13% 141
2023
Q1 		– Sell
-64
Closed -$4.33K – 1148
2022
Q4 		$4.33K Sell
64
-68
-52% -$3.99K ﹤0.01% 893
2022
Q3 		$7K Buy
132
+64
+94% +$3.43K ﹤0.01% 810
2022
Q2 		$4K Buy
+68
New +$3.77K ﹤0.01% 880
2020
Q2 		– Sell
-17,060
Closed -$514K – 1111
2020
Q1 		$514K Sell
17,060
-400
-2% -$11.9K 0.32% 102
2019
Q4 		$505K Hold
17,460
– – 0.23% 147
2019
Q3 		$451K Hold
17,460
– – 0.23% 145
2019
Q2 		$446K Hold
17,460
– – 0.23% 141
2019
Q1 		$457K Hold
17,460
– – 0.24% 138
2018
Q4 		$402K Hold
17,460
– – 0.28% 142
2018
Q3 		$412K Sell
17,460
-600
-3% -$14.6K 0.24% 168
2018
Q2 		$416K Buy
18,060
+60
+0.3% +$1.43K 0.24% 163
2018
Q1 		$443K Hold
18,000
– – 0.27% 147
2017
Q4 		$483K Buy
+18,000
New +$458K 0.3% 126

Other funds holding NVO

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
MCP
Martin Capital Partners Eugene, Oregon $279M AUM 18.87% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EIA
Eastover Investment Advisors Charlotte, North Carolina $257M AUM 14.8% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
BFA
Benedict Financial Advisors Atlanta, Georgia $504M AUM 20.67% 1-Year Est. Return
HWA
Heartwood Wealth Advisors Richmond, Virginia $1.27B AUM 11.08% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
RI
Ridgewood Investments Springfield, New Jersey $271M AUM

Investors Research Corp's NVO Position: Q3 2026 in Review

Investors Research Corp reduced its Novo Nordisk (NVO) stake by 2.2% in Q3 2026, selling an estimated $18.4K and leaving 17,825 shares worth $676K. The position accounts for 0.12% of the portfolio, ranked #136.

Investors Research Corp first reported a position in NVO in Q4 2017 and has held it in 16 quarters since. The position peaked at $874K in Q2 2026. 64 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Investors Research Corp held 17,825 shares of Novo Nordisk worth $676K as of Q3 2026.
  • Investors Research Corp sold 400 Novo Nordisk shares in Q3 2026, an estimated $18.4K.
  • Novo Nordisk made up 0.12% of Investors Research Corp's portfolio in Q3 2026, its #136 holding.
  • Investors Research Corp first reported a position in Novo Nordisk in Q4 2017 and has held it in 16 quarters since.
  • Investors Research Corp's Novo Nordisk position peaked at $874K in Q2 2026.
  • 64 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Investors Research Corp's 13F filing for Q3 2026, filed 7 Oct 2026.